

RECEIVED
CENTRAL FAX CENTER

APR 21 2004

Amendments to the Claims

This listing of claims will replace all prior versions and listing of claims in the application.

1-28. (Canceled)

29. (Amended) A pharmaceutical formulation [.] comprising a core and core materials, wherein the core materials comprise therapeutically effective amounts of an IBAT inhibitor compound and a bile acid binder and optional pharmaceutically acceptable excipients, and wherein the core material comprising the bile acid binder is coated with a layer [coating-layered] for the targeted release of the bile acid binder in the colon.

30-32. (Canceled)

33. (Amended) A pharmaceutical formulation [.] comprising a core and core materials, wherein the core materials comprise therapeutically effective amounts of an IBAT inhibitor compound and a bile acid binder and optional pharmaceutically acceptable excipients, and wherein the core material comprising the IBAT inhibitor compound is coated with a layer [coating-layered] for the targeted release of the IBAT inhibitor compound in the ileum and the core material comprising bile acid binder is coated with a layer [coating-layered] for the targeted release of the bile acid binder in the colon.

34. (Amended) A method for the [~~prophylactic or~~] therapeutic treatment of a subject suffering from, or susceptible to hypercholesterolemia, wherein the method comprises administering to the subject a therapeutically effective amount of an IBAT inhibitor compound and a bile acid binder, wherein the bile acid binder is administered for the [~~prophylactic or~~] therapeutic treatment of diarrhea during administration of the IBAT inhibitor.

35. (Amended) A method for the [~~prophylactic or~~] therapeutic treatment of a subject suffering from, or susceptible to, diarrhea during administration of an IBAT inhibitor compound, comprising administering to the subject a pharmaceutical formulation comprising a core and core materials, wherein the core materials comprise therapeutically effective amounts of a bile acid binder and optional pharmaceutically acceptable excipients,

and where in the core material comprising the bile acid binder is ~~[coating-layered]~~
coated with a layer for targeted release of the bile acid binder in the colon.

36. (Previously presented) The pharmaceutical formulation according to claim 29 or 33, wherein the IBAT inhibitor compound is a low permeability drug as defined in the FDA Biopharmaceutical Classification System.
37. (Previously presented) The pharmaceutical formulation according to claim 29 or 33, wherein the bile acid binder is a resin.
38. (Previously presented) The pharmaceutical formulation according to claim 29 or 33, wherein the IBAT inhibitor compound and the bile acid binder are administered simultaneously, separately or sequentially.
39. (Previously presented) The pharmaceutical formulation according to claim 29 or 33, wherein the IBAT inhibitor compound comprises a benzothiazepine having IBAT inhibiting properties.
40. (Previously presented) The pharmaceutical formulation according to claim 39, wherein the benzothiazepine is 1,4-benzothiazepine or a 1,5-benzothiazepine.
41. (Previously presented) The method according to claim 34 or 35, wherein the IBAT inhibitor compound is a low permeability drug as defined in the FDA Biopharmaceutical Classification System.
42. (Previously presented) The method according to claim 34 or 35, wherein the bile acid binder is a resin.
43. (Previously presented) The method according to claim 34 or 35, wherein the IBAT inhibitor compound and the bile acid binder are administered simultaneously, separately or sequentially.
44. (Previously presented) The method according to claim 34 or 35, wherein the IBAT inhibitor compound comprises a benzothiazepine having IBAT inhibiting properties.
45. (Previously presented) The method according to claim 44, wherein the benzothiazepine is 1,4-benzothiazepine or a 1,5-benzothiazepine.